Pfizer's Paxlovid doesn't stack up as well for those who are vaccinated, new data show - Endpoints News

Pfizer's Covid-19 antiviral may end up hauling in more than $20 billion this year, and help keep many vulnerable people out of the hospital. But new data show the pill doesn't hold up as well in vaccinated people as the unvaccinated. Updated data from the com…

In its quest to resubmit its Alzheimer’s-induced psychosis drug Nuplazid to the FDA following a CRL, Acadia Pharmaceuticals will have to face an advisory committee later this week. And agency officia… [+623 chars]

full article...